Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-05105679 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1: Experimental intervention: PF-05105679 or placebo | EXPERIMENTAL | Cohort 1 |
| Cohort 2: Experimental intervention: PF-05105679 or placebo | EXPERIMENTAL | Cohort 2 |
| Cohort 3: Experimental intervention PF-05105679 or placebo and | ACTIVE_COMPARATOR | Cohort 3 |
| Name | Type | Description |
|---|---|---|
| PF-05105679 | DRUG | Subjects will receive single ascending doses of PF-05105679 or placebo to investigate safety/tolerability and pharmacokinetics of PF-05105679 |
Inclusion Criteria: Healthy Volunteers Exclusion Criteria: Standard Healthy Volunteers
PF-05105679 is an investigational small molecule being studied in healthy volunteers. It is being evaluated in a Phase 1 clinical trial to assess its safety, tolerability, and pharmacokinetics following single ascending doses. The drug is not approved for any indication and remains in early clinical development.
PF-05105679 is being developed by Pfizer, Inc. (NYSE: PFE). The company is conducting a Phase 1 clinical trial of the drug in healthy volunteers.
PF-05105679 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 trial is a single-dose, dose-escalation study in healthy volunteers.
PF-05105679 is being studied in one completed Phase 1 clinical trial, NCT01393652, titled 'Single Dose, Dose Escalation Healthy Volunteers Study Of PF-05105679.' The trial enrolled 32 healthy male participants in Belgium and was active-controlled and double-blinded.
No alternative names for PF-05105679 have been disclosed. The drug is identified solely by its compound number PF-05105679 in clinical trial records.